ERBB2 and neoplasm: iPSC-NK cells expressing the CD64/16A chimeric receptor killed EGFR+/HER2+ SKOV3 ovarian cancer cells when combined with the anti-HER2 therapeutic mAb trastuzumab, or the anti-EGFR1 monoclonal antibody cetuximab, while little anti-tumor activity killing was seen without addition of these antibodies (140).